scispace - formally typeset
D

Daniel D. Sedmak

Researcher at Ohio State University

Publications -  108
Citations -  6703

Daniel D. Sedmak is an academic researcher from Ohio State University. The author has contributed to research in topics: Antigen & Transplantation. The author has an hindex of 46, co-authored 108 publications receiving 6455 citations. Previous affiliations of Daniel D. Sedmak include Nationwide Children's Hospital.

Papers
More filters
Journal ArticleDOI

Effect of fixatives and tissue processing on the content and integrity of nucleic acids.

Mythily Srinivasan, +2 more
- 01 Dec 2002 - 
TL;DR: The purpose of this review is to provide an overview of the methods of human tissue acquisition, fixation, and preservation and the parameters of procurement and fixation that affect the quality of the tissues at the molecular level are discussed.
Journal ArticleDOI

Human Cytomegalovirus Inhibits Major Histocompatibility Complex Class II Expression By Disruption of the Jak/Stat Pathway

Daniel M. Miller, +6 more
- 02 Mar 1998 - 
TL;DR: It is demonstrated that both a clinical isolate and a laboratory strain of HCMV inhibit inducible MHC class II expression at the cell surface and at RNA level in human endothelial cells and fibroblasts.
Journal Article

Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport.

James L. Leach, +5 more
- 15 Oct 1996 - 
TL;DR: It is suggested that the placental hFcRn heterodimer may transport IgG to the fetus by a mechanism in which maternal IgG is pinocytosed nonspecifically and then carried to fetal tissues by a pH gradient from acidic endosomes to the pH-neutral basolateral surface of the syncytiotrophoblast.
Journal Article

Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction.

Daniel M. Miller, +4 more
- 15 May 1999 - 
TL;DR: This investigation is the first to report inhibition of type I IFN signaling by a herpesvirus, and it is proposed that this novel immune escape mechanism is a major means by which HCMV is capable of escaping host immunity and establishing persistence.
Journal ArticleDOI

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

W J Waldman, +6 more
- 27 Sep 1999 - 
TL;DR: Findings imply that leflunomide, an effective immunosuppressive agent, shows potential to concurrently attenuate a major complication of Immunosuppression, CMV disease, by a novel mechanism of antiviral activity.